CMN Weekly (20 December 2024) - Your Weekly CRISPR...
CMN Weekly
Dec. 20, 2024
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
ADARx Pharmaceuticals
Company Type: Therapeutic development
Main focus: Developing novel treatments for several genetic, cardiometabolic, and central nervous system diseases through RNA targeting
Company stage: Clinical
Diseases: Various genetic, cardiometabolic, complement-mediated, and central nervous system diseases
Genome-editing tool: RNA editing
Funding stage: Series C
Location: San Diego, California, USA
Website: https://www.adarx.com/
Pipeline: www.adarx.com/our-technology/
Partners:
ADARx Pharmaceuticals is a clinical-stage biotechnology company focused on developing RNA-targeting therapeutics. The company utilises proprietary oligonucleotide technologies for RNA inhibition, degradation, and editing, along with delivery systems including the PLR™ (Preeminent Liver RNA) platform and SPE™ (Sequence Specific Platform Enhancement) technology. ADARx's pipeline includes treatments for genetic, cardiometabolic, complement-mediated, and central nervous system diseases.
